8 completed. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow Dextrose: new trials by email Literature Review of Dextrose trials Research Report on Dextrose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) MK-5720, Placebo to MK-5720, MK-8189 - Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2023-09-15 | 2025-03-04 |
| Pleurodesis Using Hypertonic Glucose to Treat Post-operative Air Leaks 50 mL of 50% Glucose, 100 mL of 50% Glucose, 150 mL of 50% Glucose - Postoperative Air Leak | Phase 1 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 12 | 2019-09-17 | 2021-05-12 |
| Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 69 | 2017-08-16 | 2019-11-15 |
| Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 33 | 2017-04-12 | 2019-04-01 |
| Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers Oritavancin, Dextrose - Healthy | Phase 1 | Completed | The Medicines Company | 56 | 2015-07-01 | 2023-12-19 |
| A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) MK-2640, Regular Human Insulin (RHI), Dextrose - Type 1 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 74 | 2014-11-26 | 2019-01-15 |
| Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose LY2189265, Placebo, Insulin - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 32 | 2011-02-01 | 2014-10-07 |
| Joint Injections for Osteoarthritic Knee Pain Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group - Osteoarthritis | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 98 | 2004-07-01 | 2019-02-15 |
Diabetes Mellitus, Type 1 (3) · Diabetes Mellitus, Type 2 (3) · Osteoarthritis (1) · Schizophrenia (1)
Merck Sharp & Dohme LLC (4) · Eli Lilly and Company (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · The Medicines Company (1) · University of Wisconsin, Madison (1)
United States (5) · Canada (1) · Germany (1)
PMID 22515800, PMID 23690322, PMID 24635447, PMID 30125349, PMID 35390172
K23AT001879 (1)